In silico discovery of a FOXM1 driven embryonal signaling pathway in therapy resistant neuroblastoma tumors

[1]  Donald R. Polaski,et al.  Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma , 2018, Nature Genetics.

[2]  R. Wilson,et al.  The Dynamic Epigenetic Landscape of the Retina During Development, Reprogramming, and Tumorigenesis , 2017, Neuron.

[3]  J. Rehg,et al.  MYCN induces neuroblastoma in primary neural crest cells , 2017, Oncogene.

[4]  Shan Wang,et al.  microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma , 2016, Clinical Cancer Research.

[5]  David T. W. Jones,et al.  Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. , 2016, European journal of cancer.

[6]  John T. Powers,et al.  Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma , 2016, Nature.

[7]  E. Lam,et al.  Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance , 2016, Current drug targets.

[8]  F. Westermann,et al.  Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition , 2015, Clinical Cancer Research.

[9]  M. Bollen,et al.  MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells , 2015, Bioscience reports.

[10]  Ash A. Alizadeh,et al.  Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .

[11]  F. Speleman,et al.  Characterization of the genome-wide TLX1 binding profile in T-cell acute lymphoblastic leukemia , 2015, Leukemia.

[12]  J. Vandesompele,et al.  Identification of miRNAs contributing to neuroblastoma chemoresistance , 2015, Computational and structural biotechnology journal.

[13]  A. Sharrocks,et al.  Deregulation of the FOXM1 target gene network and its coregulatory partners in oesophageal adenocarcinoma , 2015, Molecular Cancer.

[14]  K. Bhat,et al.  EZH2 Protects Glioma Stem Cells from Radiation-Induced Cell Death in a MELK/FOXM1-Dependent Manner , 2015, Stem cell reports.

[15]  Michael V. Gormally,et al.  Suppression of the FOXM1 transcriptional program via novel small molecule inhibition , 2014, Nature Communications.

[16]  E. Lam,et al.  FOXM1: An emerging master regulator of DNA damage response and genotoxic agent resistance , 2014, Biochimica et biophysica acta.

[17]  F. Speleman,et al.  MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation , 2014, Oncotarget.

[18]  B. Katzenellenbogen,et al.  The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells , 2014, Breast Cancer Research.

[19]  Jeong-Hyeon Choi,et al.  MEIS2 is essential for neuroblastoma cell survival and proliferation by transcriptional control of M-phase progression , 2014, Cell Death and Disease.

[20]  David P. Kreil,et al.  The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance , 2014, Nature Biotechnology.

[21]  Stein Aerts,et al.  iRegulon: From a Gene List to a Gene Regulatory Network Using Large Motif and Track Collections , 2014, PLoS Comput. Biol..

[22]  Mariano J. Alvarez,et al.  Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. , 2014, Cancer cell.

[23]  Kaushal Joshi,et al.  Multi-Kinase Inhibitor C1 Triggers Mitotic Catastrophe of Glioma Stem Cells Mainly through MELK Kinase Inhibition , 2014, PloS one.

[24]  W. Weiss,et al.  The prenatal origins of cancer , 2014, Nature Reviews Cancer.

[25]  J. Decaprio,et al.  The DREAM complex: master coordinator of cell cycle-dependent gene expression , 2013, Nature Reviews. Cancer.

[26]  John Anderson,et al.  New Strategies in Neuroblastoma: Therapeutic Targeting of MYCN and ALK , 2013, Clinical Cancer Research.

[27]  James A. DeCaprio,et al.  The DREAM complex: master coordinator of cell cycle-dependent gene expression , 2013, Nature Reviews Cancer.

[28]  K. Stegmaier,et al.  Targeting MYCN in neuroblastoma by BET bromodomain inhibition. , 2013, Cancer discovery.

[29]  Kaushal Joshi,et al.  MELK-Dependent FOXM1 Phosphorylation is Essential for Proliferation of Glioma Stem Cells , 2013, Stem cells.

[30]  H. Klocker,et al.  The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer , 2013, Journal of Molecular Medicine.

[31]  X. Chen,et al.  The Forkhead Transcription Factor FOXM1 Controls Cell Cycle-Dependent Gene Expression through an Atypical Chromatin Binding Mechanism , 2012, Molecular and Cellular Biology.

[32]  Jan Koster,et al.  Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification , 2012, Proceedings of the National Academy of Sciences.

[33]  E. Lam,et al.  Binding of FoxM1 to G2/M gene promoters is dependent upon B-Myb. , 2012, Biochimica et biophysica acta.

[34]  F. Speleman,et al.  Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice , 2012, Science Translational Medicine.

[35]  R. Stallings,et al.  Modulation of Neuroblastoma Disease Pathogenesis By An Extensive Network of Epigenetically Regulated MicroRNAs , 2012, Oncogene.

[36]  Ju-Seog Lee,et al.  Abstract 2962: FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair , 2012 .

[37]  David T. W. Jones,et al.  Biological and clinical heterogeneity of MYCN-amplified medulloblastoma , 2012, Acta Neuropathologica.

[38]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[39]  D. Zwijnenburg,et al.  Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes , 2012, Nature.

[40]  A. Naranjo,et al.  miRNA Expression Profiling Enables Risk Stratification in Archived and Fresh Neuroblastoma Tumor Samples , 2011, Clinical Cancer Research.

[41]  A. Tyner,et al.  FoxM1 in tumorigenicity of the neuroblastoma cells and renewal of the neural progenitors. , 2011, Cancer research.

[42]  A. Maya-Mendoza,et al.  B‐Myb is Critical for Proper DNA Duplication During an Unperturbed S Phase in Mouse Embryonic Stem Cells , 2010, Stem cells.

[43]  G. Raschellà,et al.  Addiction of MYCN Amplified Tumours to B-MYB Underscores a Reciprocal Regulatory Loop , 2010, Oncotarget.

[44]  K. Sermon,et al.  Derivation, culture, and characterization of VUB hESC lines , 2010, In Vitro Cellular & Developmental Biology - Animal.

[45]  Hannele Ruohola-Baker,et al.  Characterization of microRNAs involved in embryonic stem cell states. , 2010, Stem cells and development.

[46]  Ping Jin,et al.  MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells , 2009, Journal of Translational Medicine.

[47]  Haifan Lin,et al.  MicroRNAs: key regulators of stem cells , 2009, Nature Reviews Molecular Cell Biology.

[48]  Atul J Butte,et al.  MicroRNA profiling of human-induced pluripotent stem cells. , 2009, Stem cells and development.

[49]  Pieter Mestdagh,et al.  High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA , 2008, Nucleic acids research.

[50]  W. L. Ruzzo,et al.  MicroRNA Discovery and Profiling in Human Embryonic Stem Cells by Deep Sequencing of Small RNA Libraries , 2008, Stem cells.

[51]  John M. Maris,et al.  High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma , 2008, Proceedings of the National Academy of Sciences.

[52]  D. Gary Gilliland,et al.  Activating mutations in ALK provide a therapeutic target in neuroblastoma , 2008, Nature.

[53]  F. Slack,et al.  let-7 microRNAs in development, stem cells and cancer. , 2008, Trends in molecular medicine.

[54]  A. Regev,et al.  An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.

[55]  P. Knoepfler.  Why myc? An unexpected ingredient in the stem cell cocktail. , 2008, Cell stem cell.

[56]  Frank Speleman,et al.  Imperfect protection: NEPA at 35 years. , 2004, Genome Biology.

[57]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[58]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[59]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[60]  S. Elledge,et al.  Dicer is essential for mouse development , 2003, Nature Genetics.

[61]  F. Alt,et al.  Transposition and amplification of oncogene-related sequences in human neuroblastomas , 1983, Cell.

[62]  Amarendra S. Yavatkar,et al.  StemCellDB: the human pluripotent stem cell database at the National Institutes of Health. , 2013, Stem cell research.